Novo Nordisk (NVO) saw a significant stock price increase today, largely driven by positive clinical trial results for its new-generation GLP-1 receptor agonist, amycretin. According to the company’s Phase II clinical trial data, patients with type 2 diabetes treated with amycretin—combining weekly subcutaneous injections and daily oral administration—experienced an average weight loss of 14.5% after 36 weeks. This progress strengthens Novo Nordisk’s competitiveness in the GLP-1 drug segment, and amycretin has now advanced to Phase III clinical trials for obesity. Additionally, the company expects its oral semaglutide formulation to receive approval from the U.S. Food and Drug Administration (FDA) by the end of the year, which is anticipated to further expand its product portfolio.
Despite the positive developments with amycretin, Novo Nordisk faces increasingly fierce market competition. Its main competitor, Eli Lilly (LLY), has seen rapid growth with its drug tirzepatide (brand names: Mounjaro and Zepbound), posing a strong challenge in the obesity treatment sector. In response, Novo Nordisk has adopted an aggressive price reduction strategy, lowering the out-of-pocket monthly cost for its semaglutide drugs (brand names: Ozempic and Wegovy) from $499 to $349, aligning with the pricing levels of Eli Lilly and platforms like TrumpRx. This adjustment aims to improve drug accessibility and regain market share in a market projected to reach $150 billion by 2035.
Novo Nordisk’s challenges are not limited to Eli Lilly; they also include compounded semaglutide sold by telemedicine companies such as Hims & Hers Health. These companies offer compounded drugs at prices as low as $199 per month, even though the shortage of semaglutide was resolved earlier this year. Novo Nordisk is directly addressing this threat through its price reduction strategy, reducing patients’ incentive to choose compounded alternatives. At the same time, the company is preparing for the launch of its oral semaglutide, emphasizing supply sufficiency and the potential preference for oral formulations among patients, which may help further consolidate its market position.
Novo Nordisk’s recent stock performance reflects market recognition of its strategic adjustments and progress with new drugs. By combining next-generation drug development, aggressive pricing, and optimized formulation supply, the company aims to maintain its competitiveness in the popular GLP-1 receptor agonist field. Although price reductions may impact profit margins in the short term, expanding patient access and improving drug accessibility are expected to drive Novo Nordisk’s sustained growth in the long run.
